Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Uncomplicated gonorrhea

10

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

4

US Previously Marketed

4

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bacterial penicillin-binding protein

8

Solute carrier family 22 member 11

4

Solute carrier family 22 member 6

4

Solute carrier family 22 member 8

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

8

Phase II

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1981

4

1984

4

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

10

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

8

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Hoffman-La Roche

4

Takeda Chemical Industries

4

Ajinomoto

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

10

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

10

FDA UNII

10

EPA CompTox

8

PUBCHEM

8

EVMPD

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER BETA-LACTAM ANTIBACTERIALS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Third-generation cephalosporins

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 10 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CEFTRIAXONE

75J73V1629

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

CEFOTAXIME

N2GI8B1GK7

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Lower respiratory tract infections

Urinary tract infections

Uncomplicated gonorrhea

Intra-abdominal infections

Central nervous system infections

Bone and joint infections

Skin and skin structure infections

Gynecologic infections

Cefotaxime sodium is a semisynthetic, broad spectrum cephalosporin antibiotic for parenteral administration. It’s a 3rd Generation Cephalosporin that is FDA approved for the treatment of lower respiratory tract infections, genitourinary infections, g...

ynecologic infections, bacteremia/septicemia, skin and skin structure infections, intra-abdominal infections, bone and/or joint infections and central nervous system infections. The bactericidal activity of cefotaxime sodium results from inhibition of cell wall synthesis. Cefotaxime sodium has in vitro activity against a wide range of gram-positive and gram-negative organisms. Cefotaxime sodium has a high degree of stability in the presence of ß-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics. Common adverse reactions include injection site pain, injection site phlebitis, rash, diarrhea, vomiting. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.

CEFPIMIZOLE

24S58UHU7N

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Conditions:

Uncomplicated gonorrhea

Obstetric and gynecologic infections

Cefpimizole is an antibiotic of broad spectrum developed in Japan for the treatment of such conditions as uncomplicated gonorrhea and gynecologic infections. The drug was tested in clinical trials, however, its development was terminated.

CEFTRIAXONE, (E)-

8596N5F144

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

CEFTRIAXONE SODIUM ANHYDROUS

R598PB148Q

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

CEFTRIAXONE SODIUM

023Z5BR09K

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

Sodium (6R,7R)-3-[(acetyloxy)methyl]-7-[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

GE3J4ZL28E

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Lower respiratory tract infections

Urinary tract infections

Uncomplicated gonorrhea

Intra-abdominal infections

Central nervous system infections

Bone and joint infections

Skin and skin structure infections

Gynecologic infections

Cefotaxime sodium is a semisynthetic, broad spectrum cephalosporin antibiotic for parenteral administration. It’s a 3rd Generation Cephalosporin that is FDA approved for the treatment of lower respiratory tract infections, genitourinary infections, g...

ynecologic infections, bacteremia/septicemia, skin and skin structure infections, intra-abdominal infections, bone and/or joint infections and central nervous system infections. The bactericidal activity of cefotaxime sodium results from inhibition of cell wall synthesis. Cefotaxime sodium has in vitro activity against a wide range of gram-positive and gram-negative organisms. Cefotaxime sodium has a high degree of stability in the presence of ß-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics. Common adverse reactions include injection site pain, injection site phlebitis, rash, diarrhea, vomiting. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.

CEFOTAXIME, E-

5KTC59K32X

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Lower respiratory tract infections

Urinary tract infections

Uncomplicated gonorrhea

Intra-abdominal infections

Central nervous system infections

Bone and joint infections

Skin and skin structure infections

Gynecologic infections

Cefotaxime sodium is a semisynthetic, broad spectrum cephalosporin antibiotic for parenteral administration. It’s a 3rd Generation Cephalosporin that is FDA approved for the treatment of lower respiratory tract infections, genitourinary infections, g...

ynecologic infections, bacteremia/septicemia, skin and skin structure infections, intra-abdominal infections, bone and/or joint infections and central nervous system infections. The bactericidal activity of cefotaxime sodium results from inhibition of cell wall synthesis. Cefotaxime sodium has in vitro activity against a wide range of gram-positive and gram-negative organisms. Cefotaxime sodium has a high degree of stability in the presence of ß-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics. Common adverse reactions include injection site pain, injection site phlebitis, rash, diarrhea, vomiting. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.

CEFOTAXIME SODIUM

258J72S7TZ

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Lower respiratory tract infections

Urinary tract infections

Uncomplicated gonorrhea

Intra-abdominal infections

Central nervous system infections

Bone and joint infections

Skin and skin structure infections

Gynecologic infections

Cefotaxime sodium is a semisynthetic, broad spectrum cephalosporin antibiotic for parenteral administration. It’s a 3rd Generation Cephalosporin that is FDA approved for the treatment of lower respiratory tract infections, genitourinary infections, g...

ynecologic infections, bacteremia/septicemia, skin and skin structure infections, intra-abdominal infections, bone and/or joint infections and central nervous system infections. The bactericidal activity of cefotaxime sodium results from inhibition of cell wall synthesis. Cefotaxime sodium has in vitro activity against a wide range of gram-positive and gram-negative organisms. Cefotaxime sodium has a high degree of stability in the presence of ß-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics. Common adverse reactions include injection site pain, injection site phlebitis, rash, diarrhea, vomiting. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.

CEFPIMIZOLE SODIUM

X4628IMC52

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Conditions:

Uncomplicated gonorrhea

Obstetric and gynecologic infections

Cefpimizole is an antibiotic of broad spectrum developed in Japan for the treatment of such conditions as uncomplicated gonorrhea and gynecologic infections. The drug was tested in clinical trials, however, its development was terminated.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1